Reference number(s)
7547-D

This document applies to the following:

Formulary	Applies
Standard Control (SF)	☐
Standard Control Choice (SCCF)	☐
Preferred Drug Plan Design (PDPD)	☐
Advanced Control Specialty (ACSF)	☐
Advanced Control Specialty Choice (ACSCF)	☐
Managed Medicaid Template (MMT)	☐
Marketplace (MF)	☐
Aetna Small Group Affordable Care Act (SG ACA) Aetna Health Exchange (AHE)	☐
Value (VF)	☑

Formulary	Applies
New to Market (NTM)	☐
Standard Formulary Chart (SFC)	☐
Basic Control Chart Preferred Drug Plan Design (BCC PDPD)	☐
Advanced Control Specialty Formulary Chart (ACSFC)	☐
Value Formulary Chart (VFC)	☑
Medical Benefit	☐
Medical Benefit: Advanced Biosimilars First	☐
Combined Benefit Management (CBM)	☐
Combined Benefit Management Pharmacy (CBMP)	☐
Medical Benefit Managed Medicaid (MMMB)	☐

Exceptions Criteria
Idiopathic Pulmonary Fibrosis (IPF)

This document informs prescribers of preferred products and provides an exception process for targeted products through prior authorization.

These criteria were developed to align with the following: Value Formulary (VF) and Value Formulary Chart (VFC).

Plan Design Summary

This program applies to the idiopathic pulmonary fibrosis (IPF) products specified in this document. Coverage for targeted products is provided based on clinical circumstances that would exclude the use of the preferred product and may be based on previous use of a product. The coverage review process will ascertain situations where a clinical exception can be made. This program applies to members who are new to treatment with a targeted product for the first time.

Each referral is reviewed based on all utilization management (UM) programs implemented for the client.

Table. Idiopathic Pulmonary Fibrosis (IPF) Products

Medications considered formulary or preferred on your plan may still require a clinical prior authorization review.

	Product(s)
Preferred	• nintedanib (generic) • pirfenidone (generic)
Target	• Esbriet (pirfenidone) • Ofev (nintedanib)

Exception Criteria

This program applies to members requesting treatment for an indication that is FDA-approved for the preferred product.

Esbriet

Coverage for Esbriet is provided when both of the following criteria are met:

- Member has a documented intolerable adverse event to generic pirfenidone, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
- Member has a documented inadequate response or intolerable adverse event with the preferred product nintedanib.

Ofev

Coverage for Ofev is provided when both of the following criteria are met:

- Member has a documented intolerable adverse event to generic nintedanib, and the adverse event was not an expected adverse event attributed to the active ingredient as described in the prescribing information.
- Member has a documented inadequate response or intolerable adverse event with the preferred product pirfenidone.

References

1. Esbriet [package insert]. Scottsdale, AZ: Legacy Pharma USA Inc.; June 2025.
2. Nintedanib [package insert]. Parsippany, NJ: Edenbridge Pharmaceuticals, LLC; July 2026.
3. Ofev [package insert]. Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; May 2025.
4. Pirfenidone [package insert]. Berkeley Heights, NJ: Laurus Generics Inc.; March 2025.